{
    "clinical_study": {
        "@rank": "56924", 
        "acronym": "PLT SR PMOS", 
        "arm_group": {
            "arm_group_label": "Pletaal"
        }, 
        "brief_summary": {
            "textblock": "This is a Post Marketing Observational Study of cilostazol (Pletaal\u00ae SR capsule). As this\n      study is observational in nature to collect the safety data after administrating the Pletaal\n      SR capsule, from baseline to 16 weeks."
        }, 
        "brief_title": "Pletaal SR Post Marketing Observational Study", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Treatment of Ischemic Symptom and Prevention of Recurrence of Cerebral Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Infarction", 
                "Stroke", 
                "Infarction", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted in a prospective, single-arm, multi-center format. As this\n      study is observational in nature, the patient's follow-up is not prescriptive in nature and\n      must be left up to the judgment of the physician (investigator), within the period of\n      observation set forth in the protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients must meet all of the following inclusion criteria to be eligible for enrollment\n        into the study :                   1. Patients who are prescribed Pletaal\u00ae SR capsule\n        treatment as per investigator's medical judgment for adults aged 19 and over.\n\n        2. Patients who gave written authorization to use their personal and health data\n                                             Physician (Investigator) will refer to the product\n        market authorization (package insert) for inclusion criteria.\n\n        Exclusion Criteria:\n\n          -  Patients presenting with any of the following will not be included in the study\n                                                                 1. Patients with hemorrhage 2.\n             Patients with congestive heart failure 3. Patients with known hypersensitivity to\n             Cilostazole or any ingredients of Pletaal\u00ae 4. Women who are pregnant or may possibly\n             become pregnant 5. Patients who is not eligible to participate this study as\n             investigator's medical judgment                                         Physician\n             (Investigator) will refer to the product market authorization (package insert) for\n             exclusion criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The patient who has below indication (1. Treatment of ischemic symptoms including\n        ulceration, pain and coldness in chronic arterial occlusion (Berger's disease,\n        arteriosclerosis obliterans, diabetic peripheral angiopathy). 2. Prevention of recurrence\n        of cerebral infarction (excluding cardiogenic cerebral embolism).)"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782833", 
            "org_study_id": "021-KOA-1201n"
        }, 
        "intervention": {
            "arm_group_label": "Pletaal", 
            "intervention_name": "Pletaal", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Ji Yoon Jung"
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyungpook National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ji Yoon Jung", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jun Hong Lee"
                }, 
                "facility": {
                    "address": {
                        "city": "Kyunggido Goyangsi", 
                        "country": "Korea, Republic of", 
                        "zip": "410-719"
                    }, 
                    "name": "NHIC Ilsan Hospital"
                }, 
                "investigator": {
                    "last_name": "Jun Hong Lee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jae Myeon Jung"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "100-032"
                    }, 
                    "name": "Inje University Seoul Pail Hospital"
                }, 
                "investigator": {
                    "last_name": "Jae Myeon Jung", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Man Ho Kim"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University"
                }, 
                "investigator": {
                    "last_name": "Man Ho Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Post Marketing Observational Study to Evaluate the Safety of Pletaal\u00ae SR Capsule", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The incidence rate and the number of AE/ADRs", 
            "safety_issue": "Yes", 
            "time_frame": "Follow-up at least once from baseline to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782833"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The incidence rate of Tarchycardia and Palpitation after Pletaal\u00ae SR capsule administration", 
                "safety_issue": "Yes", 
                "time_frame": "Follow-up at least once from baseline to 16 weeks"
            }, 
            {
                "measure": "The number and percentage of drop-out patients according to Aes", 
                "safety_issue": "Yes", 
                "time_frame": "Follow-up at least once from baseline to 16 weeks"
            }, 
            {
                "measure": "The difference between AE and drug compliance according to patient's character", 
                "safety_issue": "Yes", 
                "time_frame": "Follow-up at least once from baseline to 16 weeks"
            }
        ], 
        "source": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Ecologic or Community, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}